John D. Sheppard, MD, MMSc

Long-term supplementation with marine omega-3 fatty acid has no effect on incident clinically significant dry eye disease or reported severe symptoms of the disease, according to a study.

WAIKOLOA, Hawaii — In this video from Hawaiian Eye 2022, John D. Sheppard, MD, MMSc, discusses the importance of clinical adenovirus testing.

KOLOA, Hawaii — At Hawaiian Eye 2020, John D. Sheppard, MD, MMSc, discusses three treatment options for neurotrophic keratitis: nerve growth factor, cryopreserved amniotic membrane and neurostimulation.

WAIKOLOA, Hawaii — At Hawaiian Eye 2019, John D. Sheppard, MD, MMSc, shares his practice’s experience with mixing and matching premium IOLs in patients’ dominant and non-dominant eyes, customizing vision to individual patient characteristics.

LOS ANGELES ― John D. Sheppard, MD, MMSc, explains at the Ophthalmology Innovation Summit how the TrueTear from Allergan works to stimulate the trigeminal nerve in a novel dry eye treatment approach.

KOLOA, Hawaii ― At Hawaiian Eye 2017, John D. Sheppard, MD, MSSc, anticipates the introduction of neurostimulation as a disruptive innovation that will help patients with dry eye manage their disease.

Steroids are an important group of agents used in fighting ocular inflammatory conditions. In fact, they are generally more potent than any non-steroidal anti-inflammatories currently available. With this in mind, it is important for physicians who prescribe these medications to understand their biochemistry and mechanisms of action. This article discusses steroid biochemistry as advances in steroid use are made.